search
Back to results

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

Primary Purpose

Fecal Incontinence

Status
Completed
Phase
Phase 1
Locations
Bulgaria
Study Type
Interventional
Intervention
Placebo control
NRL001 cream
Sponsored by
Norgine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fecal Incontinence

Eligibility Criteria

21 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

IN.1) sex: male and female (non-child-bearing potential or using medically adequate contraception

IN.2) race: Caucasian

IN.3) BW: 50 - 100 kg

IN.4) BMI: 20 - 28 kg.m-2

IN.5) age: 21 - 50 years

IN.6) type: healthy on the basis of specified criteria evaluated at the screening visit

IN.7) willing and able to provide informed consent

Exclusion Criteria:

General

EX.1) Previous participation in the trial

EX.2) Participant in any other trial during the last 90 days

EX.3) Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months

EX.4) History of any clinically relevant allergy (including hypersensitivity to the trial medications)

EX.5) Presence of acute or chronic infection

EX.6) Presence or history of any relevant co-morbidity

EX.7) Resting systolic blood pressure > 140 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg

EX.8) Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular

EX.9) Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes

EX.10) Positive serology for HBsAg, anti HBc and anti HCV

EX.11) Positive HIV test

EX.12) Positive alcohol or urine drug test on recruitment (and upon admission)

EX.13) History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol

EX.14) Smoking more than 15 cigarettes/day or equivalent of other tobacco products

EX.15) Use of prohibited medication

EX.16) Suspicion or evidence that the subject is not trustworthy and reliable

EX.17) Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard

General - all females

EX.18) Positive pregnancy test

EX.19) Lactating

EX.20) Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermicidal gel] should be used in addition).

Sites / Locations

  • University Hospital MHAPT Zaritza Johanna

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Control

Low dose NRL001

Intermediate dose NRL001

High dose NRL001

Arm Description

Placebo control

0.5% NRL001 cream

0.75% NRL001 cream

1.0% NRL001 cream

Outcomes

Primary Outcome Measures

Cmax of NRL001

Secondary Outcome Measures

AUC of NRL001
Tolerability of NRL001
Spontaneously reported adverse events will be recorded

Full Information

First Posted
July 29, 2011
Last Updated
July 29, 2011
Sponsor
Norgine
search

1. Study Identification

Unique Protocol Identification Number
NCT01406925
Brief Title
Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers
Official Title
A Randomised, Placebo-controlled, Double-blind, Cross-over Study in Healthy Men and Women to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intra-anal Doses of NRL001 for Three Doses Using a Cream Formulation Relative to a Matched Placebo Formulation for Reference
Study Type
Interventional

2. Study Status

Record Verification Date
July 2011
Overall Recruitment Status
Completed
Study Start Date
April 2007 (undefined)
Primary Completion Date
May 2007 (Actual)
Study Completion Date
June 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Norgine

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Incontinence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Placebo control
Arm Title
Low dose NRL001
Arm Type
Experimental
Arm Description
0.5% NRL001 cream
Arm Title
Intermediate dose NRL001
Arm Type
Experimental
Arm Description
0.75% NRL001 cream
Arm Title
High dose NRL001
Arm Type
Experimental
Arm Description
1.0% NRL001 cream
Intervention Type
Drug
Intervention Name(s)
Placebo control
Intervention Description
Placebo cream
Intervention Type
Drug
Intervention Name(s)
NRL001 cream
Intervention Description
Cream for single-dose intra-anal application
Primary Outcome Measure Information:
Title
Cmax of NRL001
Time Frame
30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing
Secondary Outcome Measure Information:
Title
AUC of NRL001
Time Frame
30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing
Title
Tolerability of NRL001
Description
Spontaneously reported adverse events will be recorded
Time Frame
Up to 12 hours post-dosing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: IN.1) sex: male and female (non-child-bearing potential or using medically adequate contraception IN.2) race: Caucasian IN.3) BW: 50 - 100 kg IN.4) BMI: 20 - 28 kg.m-2 IN.5) age: 21 - 50 years IN.6) type: healthy on the basis of specified criteria evaluated at the screening visit IN.7) willing and able to provide informed consent Exclusion Criteria: General EX.1) Previous participation in the trial EX.2) Participant in any other trial during the last 90 days EX.3) Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months EX.4) History of any clinically relevant allergy (including hypersensitivity to the trial medications) EX.5) Presence of acute or chronic infection EX.6) Presence or history of any relevant co-morbidity EX.7) Resting systolic blood pressure > 140 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg EX.8) Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular EX.9) Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes EX.10) Positive serology for HBsAg, anti HBc and anti HCV EX.11) Positive HIV test EX.12) Positive alcohol or urine drug test on recruitment (and upon admission) EX.13) History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol EX.14) Smoking more than 15 cigarettes/day or equivalent of other tobacco products EX.15) Use of prohibited medication EX.16) Suspicion or evidence that the subject is not trustworthy and reliable EX.17) Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard General - all females EX.18) Positive pregnancy test EX.19) Lactating EX.20) Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermicidal gel] should be used in addition).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans Gruss, MD PhD
Organizational Affiliation
Norgine
Official's Role
Study Director
Facility Information:
Facility Name
University Hospital MHAPT Zaritza Johanna
City
Sofia
Country
Bulgaria

12. IPD Sharing Statement

Learn more about this trial

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

We'll reach out to this number within 24 hrs